SCHEMBL3027410

SCHEMBL3027410

O=C(CS)Nc1ccc(O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.60
MEN1 O00255 2/20 0.56
MAPT P10636 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ALDH1A1 P00352 2/20 0.54
PEPD P12955 1/20 0.54
CA12 O43570 1/20 0.54
BRD4 O60885 1/20 0.54
NR1I2 O75469 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
MB P02144 1/20 0.54
CA3 P07451 1/20 0.54
CYP3A4 P08684 1/20 0.54
RARG P13631 1/20 0.54
TSHR P16473 1/20 0.54
ALOX5AP P20292 1/20 0.54
CA4 P22748 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1509976 0.91 MEN1 (0.64) MEN1MAPTKMT2APOLBL3MBTL1
SCHEMBL27937384 0.82 CYP1A1 (0.84) CYP1A1MEN1MAPTKMT2APOLB
SCHEMBL5804324 0.81 SMN1; SMN2 (0.59) CYP1A1MEN1MAPTKMT2APOLB
SCHEMBL20204849 0.81 MEN1 (0.55) MEN1MAPTKMT2APOLBL3MBTL1
SCHEMBL7923572 0.81 MAPT (0.59) MEN1MAPTKMT2APOLBL3MBTL1
SCHEMBL4281634 0.81 POLB (0.73) MEN1MAPTKMT2APOLBL3MBTL1
SCHEMBL7314984 0.81 ALDH1A1 (0.58) MEN1MAPTKMT2APOLBL3MBTL1
SCHEMBL7934465 0.81 KMT2A (0.73) MEN1MAPTKMT2APOLBL3MBTL1
SCHEMBL5804257 0.81 GAA (0.63) MEN1MAPTKMT2APOLBL3MBTL1
SCHEMBL253778 0.80 HDAC1 (0.65) MEN1MAPTKMT2APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263772-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM INC (US) 2023-08-24 US claimed
EP-4136072-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION Neumentum, Inc. (US) 2023-02-22 EP claimed
CN-113993846-A Compositions and methods for treating pain and/or inflammation 诺门图姆股份有限公司 2022-01-28 CN claimed
US-20220008390-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM, INC. 2022-01-13 US claimed
WO-2021211681-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM, INC. (US) 2021-10-21 WO claimed
WO-2005084663-A1 HETERO-SUBSTITUTED ACETANILIDE DERIVATES AS ANALGESIC AGENTS JANSSEN PHARMACEUTICA N.V. (US) 2005-09-15 WO claimed
US-20050182108-A1 or antipyretics; use of N-heterocyclecarboxylic acid, p-hydroxyphenyl amides or N-(p-hydroxyphenyl)-2-thio-group substituted acetamides; e.g. Pyrrolidine-2-carboxylic acid (p-hydroxyphenyl)-amide; substitute for aspirin in upper GI disease, aspirin allergy, bleeding disorders, clients on anticoagulants JANSSEN PHARMACEUTICA, N.V. (BE) 2005-08-18 US claimed
US-20230263772-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM INC (US) 2023-08-24 US disclosed
EP-4136072-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION Neumentum, Inc. (US) 2023-02-22 EP disclosed
CN-113993846-A Compositions and methods for treating pain and/or inflammation 诺门图姆股份有限公司 2022-01-28 CN disclosed
US-20220008390-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM, INC. 2022-01-13 US disclosed
WO-2021211681-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM, INC. (US) 2021-10-21 WO disclosed
EP-3108955-B1 SELF-WETTING POROUS MEMBRANES PALL CORP (US) 2017-12-06 EP disclosed
US-9018241-B2 Hetero-substituted acetanilide derivatives as analgesic agents JANSSEN PHARMACEUTICA, NV (BE) 2015-04-28 US disclosed
US-20130109863-A1 HETERO-SUBSTITUTED ACETANILIDE DERIVATIVES AS ANALGESIC AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2013-05-02 US disclosed
US-8357715-B2 Hetero-substituted acetanilide derivatives as analgesic agents JANSSEN PHARMACEUTICA, NV (BE) 2013-01-22 US disclosed
US-20100204284-A1 HETERO-SUBSTITUTED ACETANILIDE DERIVATIVES AS ANALGESIC AGENTS JANSSEN PHARMACEUTICA, N.V. (BE) 2010-08-12 US disclosed
US-7718692-B2 or antipyretics; use of N-heterocyclecarboxylic acid, p-hydroxyphenyl amides or N-(p-hydroxyphenyl)-2-thio-group substituted acetamides; e.g. Pyrrolidine-2-carboxylic acid (p-hydroxyphenyl)-amide; substitute for aspirin in upper GI disease, aspirin allergy, bleeding disorders, clients on anticoagulants JANSSEN PHARMACEUTICA, N.V. (BE) 2010-05-18 US disclosed
WO-2005084663-A1 HETERO-SUBSTITUTED ACETANILIDE DERIVATES AS ANALGESIC AGENTS JANSSEN PHARMACEUTICA N.V. (US) 2005-09-15 WO disclosed
US-20050182108-A1 or antipyretics; use of N-heterocyclecarboxylic acid, p-hydroxyphenyl amides or N-(p-hydroxyphenyl)-2-thio-group substituted acetamides; e.g. Pyrrolidine-2-carboxylic acid (p-hydroxyphenyl)-amide; substitute for aspirin in upper GI disease, aspirin allergy, bleeding disorders, clients on anticoagulants JANSSEN PHARMACEUTICA, N.V. (BE) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182108-A1 or antipyretics; use of N-heterocyclecarboxylic acid, p-hydroxyphenyl amides or N-(p-hydroxyphenyl)-2-thio-group substituted acetamides; e.g. Pyrrolidine-2-carboxylic acid (p-hydroxyphenyl)-amide; substitute for aspirin in upper GI disease, aspirin allergy, bleeding disorders, clients on anticoagulants HRH2, PTGS2, HRH4 CYP1A1 563/4885MEN1 4526/4885MAPT 4684/4885
US-20220008390-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION ADORA3, P2RX3, ADORA2A CYP1A1 1478/4885MEN1 4866/4885MAPT 4640/4885
US-20130109863-A1 HETERO-SUBSTITUTED ACETANILIDE DERIVATIVES AS ANALGESIC AGENTS OPRL1, OPRK1, AADAC CYP1A1 476/4885MEN1 4468/4885MAPT 3275/4885
US-20100204284-A1 HETERO-SUBSTITUTED ACETANILIDE DERIVATIVES AS ANALGESIC AGENTS OPRL1, OPRK1, AADAC CYP1A1 476/4885MEN1 4468/4885MAPT 3275/4885
US-20230263772-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION ADORA3, P2RX3, ADORA2A CYP1A1 1478/4885MEN1 4866/4885MAPT 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.